The latest word on lipodystrophy and mitochondrial toxicity (and old words that still resound).
Mascolini
Mark
M
D001851:Bone Diseases, Metabolic / Q000139:chemically induced; D004272:DNA, Mitochondrial / Q000032:analysis; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008060:Lipodystrophy / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D008928:Mitochondria / Q000187:drug effects*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use
D004272:DNA, Mitochondrial; D017320:HIV Protease Inhibitors; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin; D018894:Reverse Transcriptase Inhibitors